APOE and early-onset autosomal dominant Alzheimer disease: More recently, studies have suggested that olanzapine blocks apoE4-catalyzed polymerization of Aβ, showing potential cognitive benefits in Alzheimer’s disease, particularly in APOE4 carriers [17].